Skip to contentB
BridgeBio Pharma, Inc.
B
BBIOBridgeBio Pharma, Inc. Q3 2023 · 10-Q
Revenue$4.09M$4.09M+1,110.4% vs Q3 2022 Net Income-$179.49M-$179.49MN/M vs Q3 2022 EPS Diluted-$1.08-$1.08N/M vs Q3 2022 Operating Income-$157,692,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$145,657,000N/M Margins · derivedOperating margin-3854.6%+34345.4 pt vs Q3 2022
Net margin-4387.4%+37089.8 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 2, 2023 · 33 d after period end